You are here

  • Home
  • Archive
  • Volume 11, Issue 6
  • Comparison of medium to long-term outcomes of acute severe ulcerative colitis patients receiving accelerated and standard infliximab induction

Article Text

Article menu
Download PDFPDF
Education
Original research
Comparison of medium to long-term outcomes of acute severe ulcerative colitis patients receiving accelerated and standard infliximab induction
  1. David J Gibson1,
  2. Jayne Doherty1,
  3. Mairead McNally2,
  4. John Campion3,
  5. Denise Keegan1,
  6. Aine Keogh2,
  7. Una Kennedy3,
  8. Kathryn Byrne1,
  9. Laurence J Egan2,4,
  10. Susan McKiernan3,
  11. FInbar MacCarthy3,
  12. Subhasish Sengupta5,
  13. Juliette Sheridan1,
  14. Hugh E Mulcahy1,
  15. Garret Cullen1,
  16. Eoin Slattery2,
  17. David Kevans3,
  18. Glen A Doherty1
  1. 1 Department of Gastroenterology, Centre for Colorectal Disease, St Vincent's University Hospital, Dublin, Ireland
  2. 2 Department of Gastroenterology, University Hospital Galway, Galway, Galway, Ireland
  3. 3 Department of Gastroenterology, St James' Hospital, Dublin, Ireland
  4. 4 Department of Pharmacology and Therapeutics, National University of Ireland Galway, Galway, Ireland
  5. 5 Department of Gastroenterology, Our Lady of Lourdes Hospital, Drogheda, Ireland
  1. Correspondence to Dr David J Gibson, Centre for Colorectal Disease, St Vincent's University Hospital, Dublin, Ireland; gibsond{at}tcd.ie

Abstract

Introduction Accelerated dose infliximab (IFX) induction is associated with reduced short-term colectomy rate in acute severe ulcerative colitis (ASUC). Data on medium/long-term outcomes of this strategy are limited.

Aims Evaluate medium/long-term outcomes in patients receiving IFX induction for ASUC, comparing accelerated dose (AD) and standard dose (SD) induction.

Methods Retrospective study of consecutive patients admitted with corticosteroid-refractory ASUC in four tertiary referral centres within INITIative IBD research network (www.initiativeibd.ie). IFX rescue was given either as SD (weeks 0, 2, 6) or AD (<28 days) from January 2010 to September 2017. AD induction has been utilised in participating centres since 2014. Consequently SD patients were subdivided based on time period of IFX rescue: historical SD group (SD1) (2010–2013) and current SD group (SD2) (2014–2017). Primary endpoint was time to colectomy; secondary endpoint was time to IFX discontinuation if induction was complete.

Results 145 patients received rescue IFX (AD=58, SD1=32, SD2=55). Disease severity at induction was comparable between AD and SD1 groups; however, SD2 group had less severe disease: median C-reactive protein (CRP) 39, 44 and 20 mg/L for AD, SD1 and SD2 groups, respectively (p=0.026, Kruskal-Wallis); median CRP: albumin ratio was 1.4, 1.8 and 0.6 (p=0.016). Median follow-up for AD, SD1 and SD2 groups was 1.6 (IQR 1.1–3.1), 4.9 (IQR 2.6–5.5) and 1.5 (IQR 0.9–2.3) years. Time to colectomy was shorter in SD1 (log rank p=0.0013); no significant difference in time to colectomy was observed comparing AD and SD2 groups (log rank p=0.32). 123 patients (84%) completed IFX induction and received maintenance therapy. Time to IFX discontinuation was shorter in SD1 (log rank p=0.009).

Conclusion Time to colectomy is significantly prolonged with use of AD IFX in selected ASUC patients with more severe disease. Historical use of standard IFX induction for all ASUC patients is associated with inferior long-term outcomes.

  • IBD clinical
  • inflammatory bowel disease
  • infliximab

https://doi.org/10.1136/flgastro-2019-101335

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors DJG, DK and GAD were involved in study design. JD, MM, AK, JC, DK, KB, UK, HEM, SMcK, FMacC, LJE, GC, JS, SS and ES were involved in collection of data. DJG, DK and GAD were involved in analysis of data and in drafting and revisions of manuscript. All authors approved the final version of the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent for publication Not required.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Data availability statement Data are available upon reasonable request. All data relevant to the study are included in the article or uploaded as supplementary information.

    Linked Articles